Loading viewer...
investor_presentation
Format: PDF investor_presentation
Intellia is Leading the Genome Editing Revolution Corporate Overview MAY 2022 Bill, living with transthyretin amyloidosis, and his wife, Maura
Intellia is Leading the
Genome Editing Revolution
Bill, living with transthyretin amyloidosis, and his wife, Maura2
Intellia Therapeutics’ Legal Disclaimer
This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”, “we” or“our”) within themeaning ofthePrivate Securities
Litigation Reform Actof1995 .These forward -looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s beliefs and
expectations regarding :thesafety, efficacy andadvancement ofourclinical programs forNTLA -2001 forthetreatment oftransthyretin amyloidosis, NTLA -2002
forthetreatment ofhereditary angioedema, andNTLA -5001 forthetreatment ofacute myeloid leukemia pursuant toitsclinical trialapplications (“CTA”) andIND
submissions, including theexpected timing ofdata releases, regulatory filings, andtheinitiation andcompletion ofclinical trials ;theadvancement ofdevelopment
candidates including NTLA -3001 forthetreatment ofalpha -1antitrypsin deficiency (AATD) -associated lung disease, NTLA -2003 forAATD -associated liver
disease, andNTLA -6001 forCD30+lymphomas ;theability togenerate data toinitiate clinical trials andthetiming ofCTA andINDsubmissions ;theexpansion of
itsCRISPR/Cas 9technology andrelated technologies, including manufacturing anddelivery technologies, toadvance additional development candidates ;the
ability tomaintain andexpand ourrelated intellectual property portfolio, andavoid oracquire rights tovalid intellectual property ofthird parties ;theability to
demonstrate ourplatform’s modularity andreplicate orapply results achieved inpreclinical studies, including those inourNTLA -2001 ,NTLA -5001 ,andNTLA -
2002 programs, inanyfuture studies, including human clinical trials ;itsexpectations ofRewrite Therapeutics, Inc.’s(“Rewrite”) DNA writing toadvance additional
novel platform capabilities ;theability tooptimize theimpact ofourcollaborations onourdevelopment programs, including, butnotlimited to,ourcollaboration
with Regeneron Pharmaceuticals, Inc.(“Regeneron”), including ourco-development programs forhemophilia Aandhemophilia B,with AvenCell Therapeutics,
Inc.(“AvenCell ”)forthedevelopment ofuniversal CAR -Tcelltherapies, with SparingVision SAS (“SparingVision ”)forthedevelopment ofophthalmic therapies,
withKyverna Therapeutics, Inc.(“Kyverna ”)forthedevelopment ofKYV-201,andwithONK Therapeutics Ltd.(“ONK”) forthedevelopment ofengineered NKcell
therapies ;andthepotential timing andreceipt offuture milestones androyalties, orprofits, asapplicable, based onourlicense, collaboration and, ifapplicable,
co-development agreements with Regeneron, Novartis Institutes forBiomedical Research ,Avencell ,SparingVision ,Kyverna ,andONK ;thetiming ofregulatory
filings andclinical trialexecution, including dosing ofpatients, regarding ourdevelopment programs ;thepotential commercial opportunities, including value and
Preview truncated — download the full document for the complete content.
investor_presentation
84 Pages
investor_presentation
20 Pages
Veeco Instruments Inc.